A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients

In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3(+) melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were assessed by in vitro assay and delayed-type hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Vincenzo, Lunghi, Francesca, Fontana, Raffaella, Bregni, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119396/
https://www.ncbi.nlm.nih.gov/pubmed/21716850
_version_ 1782206564178853888
author Russo, Vincenzo
Lunghi, Francesca
Fontana, Raffaella
Bregni, Marco
author_facet Russo, Vincenzo
Lunghi, Francesca
Fontana, Raffaella
Bregni, Marco
author_sort Russo, Vincenzo
collection PubMed
description In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3(+) melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were assessed by in vitro assay and delayed-type hypersensitivity skin testing.
format Online
Article
Text
id pubmed-3119396
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-31193962011-06-28 A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients Russo, Vincenzo Lunghi, Francesca Fontana, Raffaella Bregni, Marco J Cancer Short Report In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3(+) melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were assessed by in vitro assay and delayed-type hypersensitivity skin testing. Ivyspring International Publisher 2011-06-01 /pmc/articles/PMC3119396/ /pubmed/21716850 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Short Report
Russo, Vincenzo
Lunghi, Francesca
Fontana, Raffaella
Bregni, Marco
A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients
title A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients
title_full A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients
title_fullStr A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients
title_full_unstemmed A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients
title_short A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients
title_sort clinical study of a cell-based mage-a3 active immunotherapy in advanced melanoma patients
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119396/
https://www.ncbi.nlm.nih.gov/pubmed/21716850
work_keys_str_mv AT russovincenzo aclinicalstudyofacellbasedmagea3activeimmunotherapyinadvancedmelanomapatients
AT lunghifrancesca aclinicalstudyofacellbasedmagea3activeimmunotherapyinadvancedmelanomapatients
AT fontanaraffaella aclinicalstudyofacellbasedmagea3activeimmunotherapyinadvancedmelanomapatients
AT bregnimarco aclinicalstudyofacellbasedmagea3activeimmunotherapyinadvancedmelanomapatients
AT russovincenzo clinicalstudyofacellbasedmagea3activeimmunotherapyinadvancedmelanomapatients
AT lunghifrancesca clinicalstudyofacellbasedmagea3activeimmunotherapyinadvancedmelanomapatients
AT fontanaraffaella clinicalstudyofacellbasedmagea3activeimmunotherapyinadvancedmelanomapatients
AT bregnimarco clinicalstudyofacellbasedmagea3activeimmunotherapyinadvancedmelanomapatients

Ejemplares similares